May 24, 2010 / 1:56 PM / 8 years ago

CORRECTED - CORRECTED-UPDATE 1-Javelin says batches of Dyloject to be withdr

(Corrects to clarify that certain batches of the drug are being withdrawn, and not the drug)

* Says white particulate matter in some Dyloject vials

* Drug awaiting FDA approval in United States

* Shares down as much as 30 pct

May 24 (Reuters) - Javelin Pharmaceuticals Inc JAV.A said the UK unit of Therabel Pharma NV, which owns commercial rights to Javelin’s post-operative pain drug Dyloject in the European Union, was withdrawing certain batches of the injectable drug from the UK market.

Shares of Javelin fell as much as 30 percent to $1.39 on the American Stock Exchange, before paring some losses to trade down 18 percent at $1.45.

Therabel Pharma UK Limited became aware of the presence of a white particulate matter in some vials of Dyloject in its supply chain and reported the matter to regulators in the UK, Javelin said in a statement.

Dyloject, which is awaiting U.S. Food and Drug Administration approval, has been marketed in the UK since December 2007, the company said.

Reporting by Shailesh Kuber in Bangalore; Editing by Aradhana Aravindan

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below